{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-062421","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.517941+00:00","generated_at":"2026-05-16T01:09:41.036073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axsome Q4 revenue $196M (+65% YoY); AXS-05 PDUFA set for April 30, 2026","bullets":["Total net product revenue Q4 $196.0M, FY $638.5M (+66% YoY); AUVELITY sales $507.1M (+74%).","Net loss Q4 $28.6M ($0.56/share), FY $183.2M ($3.68); cash $322.9M; operating loss narrowed.","sNDA for AXS-05 (Alzheimer's agitation) granted Priority Review, PDUFA target April 30, 2026.","SUNOSI generic patent litigation with Alkem settled; license delays generic entry until 2040.","Acquired AXS-17 (GABA A PAM) for epilepsy; NDA submission for AXS-12 narcolepsy expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-062421","json":"https://secwatch.observer/filing/0001193125-26-062421.json","markdown":"https://secwatch.observer/filing/0001193125-26-062421.md","text":"https://secwatch.observer/filing/0001193125-26-062421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/0001193125-26-062421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:09:41.036073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}